Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1Adenoma, Islet Cell 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3sargramostim 1montanide ISA 51 1lutetium Lu 177 dotatate 1incomplete Freund's adjuvant 1cabozantinib 1belzutifan 1X-Rays 1Temozolomide 1Sunitinib 1Phantoms, Imaging 1Methods 1Colony-Stimulating Factors 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × incomplete Freund's adjuvant × 30 days × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡